Back

The impact of the 2022 definition of pulmonary hypertension on long-term clinical outcomes in patients with heart failure with preserved ejection fraction

1 September 2024 (10:10 - 10:20)
Organised by: Logo
Congress Presentation Part of: Modern views on worsening heart failure Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Fusako Sera

Osaka University Graduate School of Medicine, Suita (Japan)

4 More presentations in this session

Presentation thumbnail
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Safety of COVID-19 vaccines regarding cardiovascular events: a systematic review and meta-analysis
Professor I. Khaheshi (Tehran, IR)
Abstract Slides Video
Presentation thumbnail
International cooperation in cardiogenic shock is key to improving outcomes: Cardiogenic Shock Working Group impacts a single-center in a developing country.
Doctor J. Ortega-Hernandez (Ciudad de Mexico, MX)
Abstract Slides Video
Presentation thumbnail
Remote management of worsening heart failure events and subsequent rate of emergency department admission
Mr J. Florence (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Modern views on worsening heart failure
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 10:10 CET
You may be interested in
thumbnail
Congress Presentation
Pulmonary hypertension in patients with heart failure with reduced ejection fraction: impact of the new definition of pulmonary hypertension
thumbnail
Congress Presentation
TAPSE/sPAP by echocardiography to detect elevated pulmonary vascular resistance> 4 WU in postcapillary pulmonary hypertension patients: insights from the French PH HF registry
thumbnail
Congress Presentation
Pulmonary hypertension due to left heart disease: first validation of the 2022 definitions in a prospective study, the PH-HF multicenter study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources